Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.21 - $5.13 $571,259 - $2.42 Million
472,115 Added 69.49%
1,151,518 $1.4 Billion
Q1 2024

May 15, 2024

BUY
$1.41 - $2.74 $957,958 - $1.86 Million
679,403 New
679,403 $1.48 Billion

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $69.9M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Superstring Capital Management LP Portfolio

Follow Superstring Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Superstring Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Superstring Capital Management LP with notifications on news.